24 assets in Breast Disorder

Therapeutic assets addressing Breast Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Trastuzumab Breast Disorder	Incepta Pharmaceuticals Ltd	P3	BB (68)
Sacubitril Valsartan Breast Disorder	Silesian Centre for Heart Diseases	P4	BB (65)
Olaparib Breast Disorder	AstraZeneca	P2	BB (64)
Capecitabine Breast Disorder	University of Southern California	P3	B (63)
Letrozole Breast Disorder	Fujian Cancer Hospital	P2/3	B (62)
Tamoxifen Breast Disorder	Fujian Cancer Hospital	P2/3	B (62)
Anastrozole Breast Disorder	Fujian Cancer Hospital	P2	B (60)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Breast Disorder	Beni-Suef University	P2	B (57)
Denosumab Breast Disorder	Alliance for Clinical Trials in Oncology	P3	B (57)
Marcaine Breast Disorder	Beni-Suef University	P2	B (57)
Exemestane Breast Disorder	Fujian Cancer Hospital	P2	CCC (53)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Breast Disorder	Institut Curie	P2	CCC (50)
Durvalumab Breast Disorder	AstraZeneca	P1/2	CCC (48)
Sarilumab Breast Disorder	University of Southern California	P1/2	CCC (48)
Herclon Breast Disorder	Incepta Pharmaceuticals Ltd	P1	CC (47)
Abemaciclib Breast Disorder	The Affiliated Hospital of Qingdao University	P1/2	CC (45)
Elacestrant Breast Disorder	Stemline Therapeutics, Inc.	P1/2	CC (45)
Palbociclib Breast Disorder	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	P1/2	CC (45)
Pertuzumab Breast Disorder	Icahn School of Medicine at Mount Sinai	P1/2	CC (45)
Atv-1601 Breast Disorder	Atavistik Bio, Inc	P1	CC (43)
Fulvestrant Breast Disorder	Atavistik Bio, Inc	P1	CC (43)
Fentanyl Breast Disorder	Medipol University	N/A	D (30)